Our focus areas
Biotech and pharmaceuticals
Advised Epitopea, a transatlantic cancer immunotherapeutics company and global leader in exploiting a new class of untapped tumour-specific antigens (TSAs), on their $13.6M (£10.3M) seed investment from a transatlantic syndicate of top-tier life sciences investors.
Advised Heqet Therapeutics, a King’s College biotech spin-out active in the field of regenerative medicine, on their £6.6m Series A financing round led by Claris Ventures and 2Invest.
Osborne Clarke has advised PharmaDrug, Inc. (Toronto, Canada) on its agreement dated May 31, 2022 with Khiron Life Sciences Corp. (Vancouver, Canada) to sell all of the outstanding shares in Pharmadrug Production GmbH, the company's wholly-owned German subsidiary.
Advised Bone Therapeutics, addressing high unmet medical needs in orthopaedics and bone diseases, on its €16 million loan financing from the European Investment Bank to support and prepare their lead asset, enhanced viscosupplement JTA-004, for future regulatory approval and commercialisation.
Advised NeRRe Therapeutics on its £20 million Series B2 financing round. The financing involved a syndicate of leading transatlantic life sciences investors led by new investor Columbus Venture Partners and existing investors Advent Life Sciences, Fountain Healthcare Partners, Forbion Capital Partners and OrbiMed.
Advised global healthcare leader, Grifols on a ~USD 1 billion strategic investment from Singapore’s sovereign wealth fund.
Advised Amphista Therapeutics, a leader in next generation targeted protein degradation (TPD) approaches, on its $53 million (£38 million) Series B financing round.
Supported global pharmaceutical client Daiichi Sankyo on several new instructions in 2021/22, including significant matters involving the supply of drugs to the NHS.
Advised Uniphar plc, an international diversified healthcare services business servicing the requirements of more than 200 multinational pharmaceutical and medical technology manufacturers, on its acquisition of UK-based brand commercialisation and pharmaceutical marketing agency, E4H; and on its acquisition of UK-based pharmaceutical distributor Devonshire Healthcare Services.
Supported on the provision of Koa's flagship Foundations App to customers and the licensing in of content to the Foundations app, the preparation of documentation for Koa's strategically important collaboration with Dr Care Anywhere, the collaboration with Dr Care Anywhere for the use of Koa's Mindset app to treat depression in patients and advice on Koa's wider suite of digital applications.
We advise Gama on bidding for high-value NHS framework agreements across the UK and play an integral role in helping the client to shape their bidding strategy.
We continue to be the sole adviser to Nutricia Advanced Medical Nutrition on all of its public procurement issues.
We were instructed by PestFix, one of the interested parties in a judicial review brought by the Good Law Project, a campaigning organisation. This case was designated as n.3 in the Lawyer’s ‘Top Cases of 2021’.
Advised AviadoBio Ltd, a pioneering gene therapy company focused on developing and delivering transformative medicines for people living with neurodegenerative disorders, on its $80 million Series A financing round.
Lucid Group and LDC
Advising the management team of Lucid Group, LDC and other shareholders on its partnership with new investor Intermediate Capital Group.
Creo Medical Group
Advising on a £36M fundraising.
Science Creates Ventures
Advising on five investments in 2021, including investments into Forefront RF and CytoSeek.
Advised long-standing client LDC together with the management team on the sale of Penn Pharma in a transaction worth £127m.
Advised on a series A investment in Belgian biotech company Univercells.
Advised Telefonica Alpha (Barcelona) on a software service and the applicability of both healthcare and medical device regulation.
Advised on raising EUR 5.7 million (USD 6.85m) as part of the successful closing of its pre-Series A round.